Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 4/20 | 0.30 |
| ▸ | FYN | P06241 | 2/20 | 0.30 |
| ▸ | YES1 | P07947 | 2/20 | 0.30 |
| ▸ | SRC | P12931 | 2/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methamoctol SCHEMBL13003427 | 0.74 | KCNH3 (0.41) | KCNH3ALDH1A1AURKAFYNYES1 | |
| SCHEMBL269774 | 0.74 | — | — | |
| SCHEMBL20657646 | 0.74 | LMNA (0.40) | ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL271630 | 0.72 | ADH1B (0.50) | MAPT | |
| SCHEMBL6762832 | 0.72 | ADH1B (0.55) | KCNH3ALDH1A1KMT2ACYP3A4LMNA | |
| SCHEMBL10577149 | 0.72 | KCNH3 (0.38) | KCNH3ALDH1A1KMT2ALMNAMAPT | |
| SCHEMBL5793891 | 0.72 | KCNH3 (0.41) | KCNH3ALDH1A1KMT2ALMNAMAPT | |
| SCHEMBL15513615 | 0.72 | — | — | |
| SCHEMBL9797214 | 0.71 | ADH1B (0.53) | LMNAMAPT | |
| SCHEMBL8518528 | 0.71 | ADH1B (0.53) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | KCNH3 665/4885ALDH1A1 260/4885AURKA 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.